Scholarlink

<p>Platelets are increasingly recognized as important contributors to tumor progression and metastatic dissemination. Platelets facilitate cancer cell survival, their safe transit through the hostile bloodstream, arrest at distant organ sites, and ultimate outgrowth into metastatic lesions. Although multiple platelet-dependent mechanisms have been implicated in cancer progression—including epithelial-mesenchymal transition and the provision of tumor-supportive growth factors—recent studies increasingly highlight immune modulation as a central mechanism underlying platelet-mediated metastasis. Accordingly, this review summarizes current evidence on the molecular and cellular mechanisms by which platelets regulate cytotoxic T lymphocyte and natural killer (NK) cell-mediated anti-tumor immune responses. Special attention is given to platelet-associated immune checkpoint pathways, including the expression and intercellular transfer of Programmed Death-Ligand 1 (PD-L1), as well as to the release of immunomodulatory mediators such as transforming growth factor-β1 (TGF-β1), thromboxane A₂ (TXA₂), and adenosine generated by platelet ectoenzymes. Finally, the potential implications of platelet-immune interactions for cancer therapy are discussed, with a particular focus on their relevance for immunotherapeutic strategies and metastatic disease control.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Platelets as regulators of anti-tumor immunity: mechanisms and clinical implications

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月5日

查看全文
  • Martin Schlesinger

摘要

Platelets are increasingly recognized as important contributors to tumor progression and metastatic dissemination. Platelets facilitate cancer cell survival, their safe transit through the hostile bloodstream, arrest at distant organ sites, and ultimate outgrowth into metastatic lesions. Although multiple platelet-dependent mechanisms have been implicated in cancer progression—including epithelial-mesenchymal transition and the provision of tumor-supportive growth factors—recent studies increasingly highlight immune modulation as a central mechanism underlying platelet-mediated metastasis. Accordingly, this review summarizes current evidence on the molecular and cellular mechanisms by which platelets regulate cytotoxic T lymphocyte and natural killer (NK) cell-mediated anti-tumor immune responses. Special attention is given to platelet-associated immune checkpoint pathways, including the expression and intercellular transfer of Programmed Death-Ligand 1 (PD-L1), as well as to the release of immunomodulatory mediators such as transforming growth factor-β1 (TGF-β1), thromboxane A₂ (TXA₂), and adenosine generated by platelet ectoenzymes. Finally, the potential implications of platelet-immune interactions for cancer therapy are discussed, with a particular focus on their relevance for immunotherapeutic strategies and metastatic disease control.